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LOHWe compared transcript expression, and chromosomal changes on a series of tumors and surrounding tissues to
determine if there is evidence of ﬁeld cancerization in colorectal cancer. Epithelial cells were isolated from tu-
mors and areas adjacent to the tumors ranging from 1 to 10 cm. Tumor abnormalities mirrored those previously
reported for colon cancer andwhile the number and size of the chromosomal abnormalitieswere greatly reduced
in cells from surrounding regions,many chromosomeabnormalitieswere discernable. Interestingly, these abnor-
malities were not consistent across the ﬁeld in the same patient samples suggesting a ﬁeld of chromosomal in-
stability surrounding the tumor. A mutator phenotype has been proposed to account for this instability which
states that the genotypes of cellswithin a tumorwould not be identical, butwould share at least a singlemutation
in any number of genes, or a selection of genes affecting a speciﬁc pathway which provide a proliferative
advantage.
© 2013 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).The following study was conducted to compare gene expression,
copy number and loss of heterozygosity (LOH) on a series of tumor
and sites distal to the tumor to determine if there is evidence of ﬁeld ef-
fect cancerization.We found chromosomal abnormalities in the isolated
tumor cells that had been previously reported in colorectal cancer. Epi-
thelial cells were isolated from regions surrounding the tumor ranging
from 1 to 10 cm for each of 12 patients. The number and size of the
chromosomal abnormalitieswere greatly reduced in these cells, howev-
er many copy number and LOH events were discernable. Interestingly,
these abnormalities were not consistent across the ﬁeld in the same pa-
tient samples suggesting a ﬁeld of chromosomal instability surrounding
the tumor. A mutator phenotype has been proposed to account for this
instability. This theory states that the genotypes of most cells within a
tumorwould not be identical, butwould share at least a singlemutation
in any number of genes. Or this could be a collection of genes affecting a
speciﬁc pathway which provide a proliferative advantage. In this sce-
nario, the tumor would develop as a heterogeneous collection of cells
all sharing a common feature of chromosomal instability. Another theo-
ry suggests that the mutator phenotype results in genetically altered
cells which then clonally expand to produce tumorigenesis, but the re-
sultant tumor carries many different clones of these original cells. Our
ﬁndings show that copy number events strongly reﬂected widespread
chromosome instability that were not consistent across sites distal to
the tumor ranging from 1 to 10 cm supporting one of the mutator phe-
notype models for ﬁeld cancerization and tumorigenesis in colorectal
cancer.gents University, 1120 15th St,
. This is an open access article under1. Introduction
Colorectal cancer (CRC) is the second leading cause of cancer-related
deaths globally with an accompanying low 5-year survival rate (~60%).
Epidemiological data show that 142,950 people in the United States
were diagnosed with colorectal cancer in 2007, including 73,183 men
and 69,767 women. [1]. CRC can be cured if detected at an early stage.
However, the early-stage disease is mostly asymptomatic; hence ap-
proximately two-thirds of patients with CRC are diagnosed at a more
advanced stage. One emerging modality of cancer risk stratiﬁcation is
via identiﬁcation of “ﬁeld carcinogenesis”. The term was ﬁrst used in
1953 in the landmark paper by Slaughter et al. They describe an area
or "ﬁeld" of epithelium that has been preconditioned by largely un-
known processes so as to predispose it towards development of cancer.
Since then, the terms "ﬁeld cancerization" and "ﬁeld defect" have been
used to describe pre-malignant tissue in which new cancers are more
likely to arise. Since then the concept ofﬁeld cancerization in clinical on-
cology has received increasing attention [3]. This interest is further mo-
tivated by the exceedingly high incidence of second primary colorectal
cancers occurring in approximately 300 to 400/100,000 patients be-
tween age 30–39 and 70 or over [4]. The predilection to develop neo-
plastic transformation should be identiﬁable throughout the diseased
organ because the genetic and environmental surroundings that result
in a neoplastic event shouldmanifest throughout the local tissuemilieu.
This ﬁeld cancerization concept is well established in a variety of malig-
nancies such as the diffuse aero-digestive injury associated with
smoking-induced lung cancer [5]. The clinical manifestation is the in-
creased incidence of tobacco-related primaries in the ﬁeld of injury
(e.g., lung, esophagus, head and neck). Genetic mutations, such as
those in the TP53 gene for example, can be found throughout thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Clinical and experimental details.
Designation
in paper
Date of
surgery
Tumor
grade
Tumor stage Samples Arrays
A 40808 MD pT3aN0pMX T, 1, 5, 10 U133, 250 K
B 81210 MD pT3pN2pMX T, 1, 5, 10 250 K
C 81610 MD pT4apN2pMX T, 1, 5, 10 U133, 250 K
D 81710 MD pT3pN2pMX T, 1, 5, 10 U133, 250 K
E 40908 PD pT3c/dpN2pMX T, 1, 5, 10 U133, 250 K
F 41008 N/A N/A T, 1, 5, 10 U133, 250 K
G 82610 MD pT3a/bpN0pMX T, 1, 5, 10 U133, 250 K
H 41108 MD pT3c/dpN0pMX T, 1, 5, 10 U133 250 K
J 50508 MD pT2pN0pMX T, 1, 5 U133, 250 K
K 90310 MD pT4apN0pMX T, 1, 5, 10 250 K
L 32708 MD pT3 T, 1, 5, U133,
N 92010 MD pT2a/bpN1pMX T, 1, 5, 10 250 K
P 92310 MD pT4apN0pMX T, 1 U133, 250 K
S 22708 PD pT3a/bpN0pMX T, 1, 5, U133
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cancerization hypothesis is the rationale for colonoscopic post-
polypectomy surveillance. Aside from the adenomatous polyp, there
have been a number of putative biomarkers that occur earlier in the
pre-dysplastic mucosa. These include gains, ampliﬁcations, losses, dele-
tions and translocationswhich are the hallmarks of chromosomal insta-
bility observed in most tumor types. Copy number alterations (CNAs)
typically seen in colorectal tumors may occur in low-grade dysplastic
adenomas and are therefore proposed asmajor factors in tumorigenesis
[6].
The exact mechanism of ﬁeld cancerization has not been well-
formulated; however theories of tumorigenesiswould likely be relevant
to address the question. One such theory was formulated for colon can-
cer in the groundbreaking study of Fearon and Voglestien in 1990 [7]
wherein they hypothesized a sequential order ofmutations in cancer as-
sociated genes. In this scenario, each successive mutation would confer
an increased proliferative advantage. Although it was shown in adeno-
carcinomas of the colon, a timeline for mutations in oncogenes correlat-
ed with carcinogenesis, this model postulates that high-grade tumors
would have accumulated mutations in each of the cancer-associated
genes. However, subsequently it has been shown that fewer than 7%
of colon cancers actually containmutations in the threemost frequently
mutated genes associated with that tumor type [8].
A second scenariowas suggested by Nowell in 1976 [9] whereby the
observed incidence rates of cancer may be explained by mutations oc-
curring at the normal rate in conjunction with multiple successive
rounds of lineage expansion and selection. In this concept of “clonal
evolution,”most of these genetic variants that arise in a tumor cell pop-
ulation do not survive. However, those few mutants that have an addi-
tional selective growth advantage expand to become predominant
subpopulations within the neoplasm. Furthermore, these selective
mutants demonstrate the characteristics of more aggressive growth
and increased “malignancy” that we recognize as tumor progression.
The continued presence of multiple subpopulations in the neoplasm
provides the basis for the heterogeneity that is also typically observed
in malignant tumors.
Along similar lines themutator phenotypemodel was also postulat-
ed in the 1970s by Loeb et al [10]. This model asserts that cancer is driv-
en more efﬁciently via multiple pathways. Therefore the genotypes of
most cells within a tumor would not be identical, but would share at
least a single mutation in any number of genes which proffer a prolifer-
ative advantage. The tumor itself would develop as a heterogeneous col-
lection of cells all sharing a common feature of chromosomal instability
and having different but overlapping patterns of mutated genes. This
theory is largely supported by recent Next-Gen sequencing evidence
which suggests that each tumor is unique and contains hundreds to
thousands of individual mutations.
In this study, we have looked at the gene expression of an enriched
population of epithelial cells derived from colon tumors and adjacent
tissues at variant distances from the tumor.We then performed concur-
rent copy number and LOH analysis on the same tumor/normal
samples to identify regions which would support the concept of ﬁeld
cancerization and the genes that map to these regions and show up or
down regulation in all of the samples studied. Using this analysis we de-
termined that LOH events are more consistent than CNAs across the
colon ﬁeld. We also found a large amount of copy number variation in
regions adjacent to the tumors, which suggest the presence of high
levels of cellular heterogeneity.
2. Materials and methods
Specimen procurement was approved through the Health Institu-
tional ReviewBoard at the State University of NewYork at Buffalo. Spec-
imens were obtained after surgical removal, and cells obtained from
non-diagnostic, excess areas of tissue. Informed consent was obtained
from study participants. The samples were de-identiﬁed and theresearchers had no contact with the human subjects. Overall, 14 tumors
and adjacent tissues were chosen for analysis, however, not all patient
samples yielded enough quality RNA at all sites distal to the original tu-
mors. Most of the tumors had a matching sample from 1 cm, 5 cm and
10 cm distal to the tumor. Transcript proﬁling was carried out on 11
samples, and of these, 7 had mRNA of adequate quality from the
tumor itself and 3 sites distal to the tumor, 3 others were missing sam-
ples at 10 cm distal to the tumor and 1 had mRNA from only tumor at
1 cm. Copy number analysis was carried out 12 specimens and each
had sufﬁcient DNA from tumor and 3 sites distal to the tumor. Nine
specimens used in the transcript expression studies overlapped with
those used in theDNA copy number studies. This information on patient
inclusion is shown in Table 1. The specimens used in the transcript ex-
pression studies for the most part, overlapped with those used in the
DNA copy number studies, however the overlap was not 100%. Also,
not all patient samples yielded enough quality RNA at all sites distal to
the original tumors. This information on patient inclusion is shown in
Table 1.
Isolation of tumor and epithelial cells: Brieﬂy, the procurement pro-
tocol involved receipt of the extirpated specimen in the operating suite,
rapid transport to the pathology department, opening and gross inspec-
tion of the specimen and removal of debriswith normal salinewashes at
37 °C, followed by exfoliation of cells with the edge of a glass slide [11].
The exfoliated cells were then placed into a microcentrifuge tube
containing PBS with 10 mM dithiothreitol (DTT), a mucolytic agent at
37 °C. During the development of this procurement protocol, elimina-
tion of mucus was found to be necessary to prevent contamination by
symbiotic bacteria present in the human intestinal tract and other
cells that may have become trapped in themucus during the exfoliation
procedure. The groups of cells that were exfoliated were further dis-
persed into single and small groups of cells using a chelating agent
(Cellstripper™, Mediatech, Herndon, VA). These washes were then
followed by further enrichment with a red blood cell lysis agent
(RBC Lysis Buffer, eBioscience). Final enrichment was achieved using
magnetic beads coated with the Ber-Ep4 antibody, which recognizes
an epitope previously documented to be expressed in colonic epithelial
cells, which is considered to be speciﬁc for this cell type [12]. The resul-
tant samples consisted of an enriched population of epithelial cells
without the associated tissue contaminating normal stromal and in-
ﬂammatory cells. The enriched cells were snap frozen in liquid nitrogen
and stored at−80 °C. Total RNA and DNA from each sample were ex-
tracted within one month of procurement. We typically isolated
~300–500 ng of each suggesting that each epithelial isolation resulted
in ~250,000 cells.
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RNA obtained from the tumors and accompanying normal tissues
was used to prepare cRNA for hybridization to the Affymetrix
U133Plus 2.0 oligonucleotide arrays as described previously [13]. This
analysis included 11 colon tumor samples and 3 corresponding control
epithelial tissues at varying distances from each of the original tumors.
All procedures were carried out as speciﬁed by the manufacturer. Fol-
lowing hybridization to the U133Plus 2.0 arrays, the resultant raw CEL
ﬁles (raw intensity ﬁles) were transferred to PARTEK Genomics Suite
version 6.5 and normalized using GCRMA (G-C Robust Multichip Aver-
age) with quantile normalization to correct for variances in distribution
patterns and GC nucleotide content. A quality inspection of the normal-
ized data was done via boxplot (data not shown).
In support of the ﬁeld cancerization theory, we hypothesized that
some genetic changes in colon cancer are uniform across the colon tis-
sue and these would be reﬂected in the transcript expression patterns.
An unbalanced repeated measure analysis of variances (ANOVA) was
performed to test for the “ﬁeld carcinogenesis” concept, with tissue
sites per patient as the repeated factor and scan date as possible con-
founding factors, using a moderated F test. Pairwise comparisons be-
tween tumor to each of the sites distal to the tumor and each of the
distal sites to another were conducted. In the meantime, the contrast
of tumor versus control sites was examined to allocate differentially
expressed genes in tumor as regular practice. We used the Benjamini–
Hochberg method [14] to adjust for p-values in multiple comparisons
within each gene in addition to false discovery rate (FDR) adjustment
across all genes. Differentially expressed genes were selected based on
an FDR-corrected p-value of 0.05 and 2-fold change or higher. In addi-
tion, principle component analysis was used to investigate possible
differential behavior of any of the samples among various distal sites
to tumor. Statistical analyses were conducted using “limma” package
in R 2.11.0.
To further investigate the mechanism of ﬁeld cancerization theory,
we decided to limit the selected genes to those with FDR adjusted p
values N0.6 in a comparison between tumors and sites distal to the
tumors. We also limited the expression differences to b0.5 fold change
across all comparisons to select for genes that had no change across
the comparisons between the tumor and the surrounding tissues. To de-
termine increased or decreased expression of genesmapping to regions
of copy number alterations or LOH event later, we created a baseline for
the entire dataset using normalization of the intensities to themean in-
tensity of all probes across all arrays whichwas 4.3. Using this approach
we determined if geneswere up or down regulated relative to the entire
dataset.
2.2. Copy number analysis using SNP array CGH
The Affymetrix GeneChip 250 KMappingAssay is designed to detect
N250,000 Single Nucleotide Polymorphisms (SNPs) in samples of geno-
mic DNA. Array experiments were performed as previously described
[13]. Brieﬂy, 250 ng of genomic DNA was digested with the restriction
enzyme STY. The assay utilizes a strategywhich reduces the complexity
of human genomicDNAup to 10 fold by ﬁrst digesting the genomicDNA
and then ligating STY adaptor sequences onto the DNA fragments. The
complexity is further reduced by a PCR procedure optimized for frag-
ments of a speciﬁed size range (200–1100 bp). Following these steps
the PCR products (amplicons) are fragmented, end-labeled, and hybrid-
ized to the array.
Following thewashing staining and scanning the .CELﬁles generated
from Affymetrix Command Console were transferred to PARTEK Geno-
mics Suite 6.6. We ﬁrst adjusted the raw probe intensities based on
the GC content of the sequence. This correction has been shown to im-
prove the accuracy of CNA calls [15]. This adjustment was followed by
probe-level normalization of signal intensity while simultaneously
adjusting for fragment length and probe sequences across all samples.The datawere then background corrected using RMA (RobustMultichip
Average) and quantile normalized. The baselinewas generated from the
250 K Mapping 270 HapMap set obtained from CEPH (Centre Etude du
Polmorphisme Humain) individuals. The resultant data was then used
to generate CNA for each sample. Detection of CN gains and losses was
performed using the Genomic Segmentation algorithm available in
PARTEK Genomics Suite to obtain the different CN state partitions.
This algorithm is similar to Hidden Markov Model (HMM) segmenta-
tion algorithm. Despite the fact that we isolated tumor and epithelial
cells from our samples, individual cells may not display the same copy
number variations. For this reason, copy number often will not fall
into biologically predicted bins and occasionally becomes a continuous
variable. Segmentation looks for changes in genomic abundance, not
regions of a speciﬁc copy number state, enabling segmentation to be
highly effective in cases where cellular heterogeneity can lead to non-
integer copy number intensities. The different segments are then de-
ﬁned as regions of locally stable copy number states and each region
is compared to the expected normal value and assigned a likelihood of
being a CNA using two one-sided t-tests. The resultant p-values are
used to ﬁlter out regions of change that are rare or due to noise. Noise
is signiﬁcant in copy number data so that the algorithmdoes not consid-
er normal at a diploid number of 2 but instead is considered a range of
±2.3. Therefore, cutoff values of 2.3 for gains and 1.7 for losses were
used and ampliﬁcations were deﬁned as states exceeding 4.5 copies.
We speciﬁed that each segmentmust contain aminimum of 10 con-
secutive ﬁltered probesets. The 250 K Mapping array has SNP probes
placed average distance of 10 KB between probes therefore the copy
number segments we are identifying are a minimal size of 100 KB.
Although, in practice, thiswill not be the case on every chromosomal re-
gion because themarker density varies signiﬁcantly across the genome.
A threshold p-value of p = 0.001 for two adjacent regions having sig-
niﬁcantly different means using a two sided t-test was implemented.
The signal to noise ratio was set at 0.3 and is estimated by the calcula-
tion of local estimates of standard deviation to determine if probes differ
from neighboring probes across all samples. This estimate determines
how robust the algorithm will be when applied to samples with highly
variant genomes. The signal to noise setting is the minimum differ-
ence between two potential consecutive settings divided by the
chromosomal variant estimate. We speciﬁed that the CNA had to occur
in at least 3/12 samples.
2.3. Loss of heterozygosity (LOH) analysis
For analysis of LOH events the raw image data from the samples was
incorporated into Genotyping Console (Affymetrix Inc., CA, USA) which
automatically generates genotype calls using the BayesianRobust Linear
Model with Mahalanobis distance classiﬁer algorithm (BRLMM). A ge-
notype and conﬁdence score is assigned for each observation. The resul-
tant .CHP ﬁle contains calls (AA, BB or AB) for each SNP probe set. The
.CHP ﬁle was then imported into Partek Genomics Suite version 6.6.
Partek analysis of LOH uses a Hidden Markov Model (HMM) to ﬁnd re-
gions that are most likely to be loss events based on the genotype error
and the expected heterozygous frequency at each SNP. We used an un-
paired analysis where the probability of observing a heterozygous SNP
in a region of LOH is the genotype error rate. In a region without LOH,
the probability of observing a heterozygous SNP is estimated using the
observed frequency from the baseline samples. The heterozygosity
rate (HET rate) is calculated as the number of AB calls/total number of
calls, therefore low het rates imply LOH. By default the frequency of het-
erozygous calls a normal region is .3. We used a het rate of b0.07 for de-
tecting LOH events. The allelic ratios for the SNPs at each reported event
were graphed and visually examined and any reported regions that
were found in areas of poor probe density or close to centromeres
were identiﬁed. The analysis limits the number of markers on the LOH
fragment to a minimum of 10. The LOH data was then assimilated and
compared with copy number and with gene expression data.
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For this analysis we identiﬁed regions which showed concordant
gains, ampliﬁcations, losses, deletions or LOH events across all samples.
We then determined if genes mapping to these regions also met the
criteria of having no signiﬁcant expression changes across all samples.
To determine if the genes of interest had relative increases or decreases
in expression they were compared to the mean normalized intensity
values which served as a baseline for these analyses.Fig. 2.Hierarchical cluster of isolated epithelial cells derived from tumors and sites 1, 5 and
10 cm distal to the tumor. The differences in expression are between the tumor and epi-
thelial cells at all sites. Note that C1 is the sample that is behaving opposite to the rest of
the epithelial sample in the second column from the right.3. Results
3.1. Gene expression analysis
The Principle Components Analysis (PCA) displayed in Fig. 1 shows
that the tumors cluster together and all of the epithelial cells, despite
their distance from the tumor, also cluster together. We compared the
tumor to each of the groups of epithelial cells at a speciﬁed distance
from the tumor. We then compared each of the epithelial groups to
each other (e.g. 1 cm VS 10 cm, 5 cm VS 10 cm, and 1 cm VS 5 cm)
and RMANOVA (Repeated Measures Analysis of Variance) showed no
differentially expressed genes between the epithelial cell groups distal
to the tumors.
Based on comparison between tumor and the distal sites from tumor
adjusting for scan date, differentially expressed genes were selected
with an FDR adjusted p value of 0.05 and a fold change of 2 fold or great-
er. Genes showing over-expression in the tumors were 7828 in number
and included TGFBI, FOXQ1, FN1, COL6A3, IGFBP7, TIMP1, ZAK, CALD1,
PHLDA1andNME (genes not showing any cross hybridization features).
Three thousand, two hundred and six genes displayed down-regulation
and included GUCA2B, AQP8, GUCA2A, CLCA4, CD177, CA4, MS4A12,
TRPM6, ABCG2, ZG16 and SLC51B. Fig. 2 shows the hierarchical clusterFig. 1. Principle Components Analysis of the gene expression data. The analysis shows the
difference between the tumor and normal cells and the similarity between the normal
cells from different regions of the colon. The one tumor that appears to the left of the
rest is one of the poorly differentiated tumors from patient E. The one on the farthest
right is the tumor from patient F, which has no tumor grade or stage associated with it.
The other samples from this patient are those clustering at the bottom left away from
the other normal samples. C1 is the sample clustering closest to the tumors.of the top differentially expressed genes, all showing larger than 50-
fold difference. The complete list of gene expression differences is avail-
able as Supplemental ﬁle 1.
This data is interesting because the studies were carried out using a
pure population of isolated epithelial cells from all of the samples and
therefore there is little contamination from stromal elements. Pathway
analysis using KEGG (Kyoto Encyclopedia of Genes and Genomes) path-
ways showed that the mismatch repair pathway had an enrichment
score of 13, a p-value of 1.43e−006 and 91% of genes in the pathway
were present in the list of gene expression alterations between tumors
and all sites distal to the tumors. The pathway is shown in Fig. 3where it
can be seen that all the genes show up-regulation except for MSH3 and
PMS2 which show no change in expression levels.
The TP53 Signaling pathwaywas also identiﬁed and in this pathway
60% of the genes in our list of differentially expressed genes are repre-
sented. TP53, ATM, ATR, CHEK1 and CHEK2 are up-regulated. The
TP53 target genes leading to cell cycle arrest include CDKN1A (p21),
YWHAQ and GADD45 which are down-regulated, however the down-
stream targets of these genes (CCND1, CDK4/6, CCNE1, CDK2, CCNB1,
CDK1) all show increased expression which would result in cell cycle
arrest.
The colorectal cancer pathway has 43% of genes present in the list
but has an enrichment factor of only 0.8. In this pathway the WNT sig-
naling and TGFB signaling, MAPK signaling, TP53 signaling and cell
cycle pathways are all shown to interact. TGFB1, TGFBR1, TGFBR2,
AXIN1, AXIN2 AKT3, PIK3CA, APPL1, RHOA, MAPK9, MAPK1, MYC,
CTNNB, CTNNB, MLH1, MSH2, MSH6 TP53 and CCND1 show increased
expression in the tumors compared to the distal epithelium and KRAS,
SAMD3, SMAD4, CYCS and JUN have reduced expression in the tumors.
We then identiﬁed genes that had no expression changes across all
samples. We used a FDR adjusted p value of N0.6 and a fold-change of
b0.5 to classify genes with no signiﬁcant differences across all samples.
There were 9365 genes which were not signiﬁcantly differently
expressed across all colon samples as shown in the Supplemental ﬁle
2 (Affymetrix hybridization controls were removed). The ﬁle contains
Affymetrix probeset ID, gene symbol and adjusted p-value. The genes
showing the highest similarity were those with an FDR-adjusted
p-value of 0.99 when comparing tumors to the normal epithelial
cells.We created a baseline from this data set by normalizing the inten-
sity of each probeset to the mean intensity of all probesets across all
samples. The data with the genes that had no expression differences
across all samples was then compared to the mean-normalized data
to determine up or down-regulation of genes mapping to the regions
of copy number alterations or LOH events.
Fig. 3. TheMismatch Repair Pathway in Eukaryotes: This pathwaywas selected as one of themost up-regulated pathways using the transcript expression analysiswhich compared tumor
cells to epithelial cells isolated from a series of sites distal to the tumor. For comparison purposes, theMSH2 gene displays a 15.85 fold-change increase (intense shading), theMSH6 has a
9.92 fold-change (medium shading) and MLH1 has a 2.6 fold-change (light shading) un-tinted molecules have no changes.
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For the analysis copy number changes, we examined the tumors and
each site separately and then applied an overlap analysis with the
targeted non-differentially expressed genes across samples to determine
if any regions exhibited gains or losses in both the tumor and regions
adjacent to tumor. Copy numbers are reported as ranges because the
Genomic Segmentation algorithm deﬁnes regions based on the number
of samples and therefore a region will be reported in 8–11/12 tumors
for example highlighting the fact thatmost stop/start regions of CN alter-
ations are not consistent.
Fig. 4 shows the copy number composites for each of the areas in the
colon, it can be seen that the tumor samples displaymany chromosome
abnormalities while in the samples obtained from the sites distal to the
tumor, the copy number events are substantially reduced. There are,
however, some regions that do not change for example most tumors
(8–11/12) had whole chromosome gain of chromosome 13 and in
many cases this was classiﬁed as whole chromosome ampliﬁcation.
The copy number gain detected in the largest number of tumors was
at chromosome 13q34 (chr13: 111,095,336–115,045,730) in 11/12 tu-
mors with an average of 4 copies (AT, BT, CT, DT, ET, FT, HT, KY, KT,
NT, PT). In samples obtained from the 1 cm distal to the tumor, thecopy number events are substantially reduced in number. The consis-
tent whole chromosome arm ampliﬁcations seen along chromosome
13 have disappeared except at 13q34 where the copy number gain of
2.5 copies has been retained in 5/12 of the samples (A1, E1, F1, H1,
and J1). This region of gain is also detected in 4 samples at 5 cm (A5,
D5, H5, and J5) and 5 samples at 10 cm from the tumor (A10, E10,
F10, H10, and J10). This 3.9 MBP region contains 67 genes and ESTs. Of
these; RAB20, MCF2L, LAMP1, GRTP1 and TMEM255B are the only
genes that are includedwhichmet the criteria of unchanged over all tu-
mors and colon samples and also show increased expression compared
to the mean normalized baseline values.
Another interesting phenomenon is that the sites 10 cm from the tu-
mors have more copy number alterations than those sites closer to the
tumor (see Fig. 4). An example of this is demonstrated on the q arm of
chromosome 8 which showed a large number of gains in the tumors
with 7 tumors having entire q arm gain. The minimal region of gain in
10/12 tumors occurred at 8q24.3 (chr8: 142,183,920–142,871,092).
The whole arm gains are not apparent in the sites distal to the tumor,
however, thisminimal region shows ampliﬁcation (more than 4 copies)
in 1–2 of the 1 cm samples and 1–3 of the 5 cm samples while 5 sam-
ples at 10 cm show ampliﬁcation of this region. This 0.6 MBP region
has 7 genes mapping to it and SLC45A4 was the only gene which
Fig. 4. Copy Number Changes in A. epithelial enriched cells isolated from colorectal tumors. B. epithelial cells isolated from 1 cmdistal to the tumor C. cells isolated from 5 cmdistal to the
tumor D. cells isolated from 10 cm distal to the tumor. Copy number gains appear to be more frequent in cells isolated from 10cm than those isolated at 1 or 5 cm suggesting a ﬁeld of
chromosome instability which is not consistent across the cells from differing distances.
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increased expression relative to the mean-normalized baseline and the
increased expression of this gene was also detected in those samples
which did not carry the ampliﬁcation.
An adjacent 3.4 MBP region on 8q24.3 (chr8: 142,963,193–
146,364,022) demonstrates the amount of instability in the region.
Fig. 5 illustrates the copy numbers and extent of the ampliﬁcation for
all 12 tumors. Seven tumors had whole q-arm ampliﬁcation or whole
chromosome ampliﬁcation and 3 tumors had punctate regions of ampli-
ﬁcation. The region becomes further segmented in the 1 cm samples
whereby some segments show losses and some gains. The samples
from the same patients show further variation in copy numbers at
5 cm and 10 cm from the tumors where further copy number variation
and some ampliﬁed regions have been detected in the samples A10 and
J10. Of the 161 genes mapping to the region only NAPRT1, PARP10,
GRINA, OPLAH, BOP1, HSF1 VPS28, KIFC2, PPP1R16A and C8orf82
showed increased expression over the normalized baseline. These
genes showed increased expression as determined by microarray,
across all samples regardless of the copy number status. For example
the gene VPS28 is over expressed in both A and C samples regardless
of the fact that A has variant number of copy numbers at different
sites in the colon in this region and C does not show any copy number
ampliﬁcation across all samples. Despite the differences in copy numbers
across the samples, the genes that map to the region show stable expres-
sion levels as determined by microarray analysis.Another adjacent region on 8q24.23 (chr8: 138,532,746–
138,601,384) shows a similar pattern of instability across the samples.
Six tumors have ampliﬁcations of this region (more than4.5 copies) and
3 have copy number gains, while the epithelial cells collected from sites
distal to the tumor showonly gains in copy number. In patient A the tumor
does not have a gain in this region while all sites distal to the tumor have
acquired a copy number gain. In patient P the gain is detected in the
tumor and at 1 cmbut not in any other samples collected from this patient.
Single copy gains on chromosome 7 were detected along the entire
chromosome in 5 tumors (AT, DT, FT, KT, and PT). Interestingly, none
of these ampliﬁcations are detected in the 1 cm, 5 cmor 10 cmsamples,
however, sample G at 1 cmhas a whole chromosome 7 gain of 2.4 aver-
age copies that was not present in the tumor cells. Minimal regions of
overlap were deﬁned by smaller regions in 4 another tumors. At
7p22.2-p22.3 (chr7: 1,923,803–2,864,607), an average of 3 copies
were detected in 9/12 tumors. In the 1 cm samples, no copy number
changes are detected in this region with the exception of the G1 gain.
In the 5 cm samples, copy gains are detected in a smaller region within
the larger region (chr7: 2,134,893–2,714,009) in samples A5, E5 and J5
copies. An ampliﬁcation is detected in the 10 cm sample A10 with 4.5
copies and, the remainder of the samples had copy number gains
(E10-2.6, F10-3.6, H10-3.0 and J10-3.4 copies). Of the 55 genesmapping
to this region, several show no changes across all samples but none
of these show increased expression over the calculated mean
baseline.
Fig. 5.Copynumber loss at chromosome8q24.3. The tumor samples A. show loss in 10/12 tumorswhile the loss changes dramatically over the samples distal to the tumor B.-D. This region
strongly supports the concept that the entire region around the tumor demonstrates chromosomal instability at the cellular level.
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Seven tumors (AT, DT, ET, JT, KT, NT and PT) had complete single
chromosome copy loss on chromosome 18 however this loss was not
detected in any of the other sites distal to the tumor.
The region showing copy number loss in the largest number of both
tumors and distal epithelial cells was at 4q21.1 (chr4: 78,188,531–
78,283,866). This small region showed loss in 6–9/12 tumors, 5–8/12
samples at 1 cm, 5-7/12 samples at 5 cm and 4/12 of the 10 cm
samples, however, no genes mapped within the region.
Genome instability is also apparent in the regions of copy number
loss. An example is seen at chromosome 10p12.33 (chr10:
18,365,392–18,451,926)whereby the tumors shows a single copy num-
ber loss in 6 samples (AT, CT, DT, GT, JT, PT). This loss is also detected in 4
of the 1 cm samples (A1 C1, F1, and P1), 4 of the 5 cm samples (A5, B5,
C5, F5) and 4 of the 10 cm samples (A10, C10, D10, P10). Samples from
patients A and C are the only ones with consistent loss. A single gene
maps to this region, the CACNB2 gene shows consistent loss across all
samples.
The whole p-arm of chromosome 8 has copy number loss in 5 tu-
mors. One region of loss on the p-arm is further deﬁned in an additional
tumor (BT, ET, DT, FT, JT, and PT) to 8p21.2 (chr8: 23,648,007–
24,720,876). The 1 cm samples show a loss in 3 patient samples
(A1, F1, and H1) in a slightly smaller region which has the same genes
mapping to it at chr8: 23,648,007–24,796,394. The 5 cm samplesshow loss of this region in 4 patients (A5, E5, F5, H5, J5) and the
10 cm samples have a loss in 5 patients (A10, E10, F10, H10, J10).
Twelve genes/ESTs map to this region and of those STC1 and ADAM7
show decreased expression compared to themean-normalized baseline.
A region on the p-arm of chromosome 11 (chr11: 34,926,681–
34,949,945) had a copy number loss in 6 tumors (CT, DT, GT, KT, NT,
PT), 5 of the 1 cm samples (B1, D1, G1, N1, P1), 5–6 of the 5 cm samples
(B5, D5, G5, K5, N5, P5) and 5 of the 10 cm samples (B10, G10, K10, N10,
P10). Of the two RefSeq genes mapping to this region PHDX did not
meet our criteria for inclusion and APIP did have a decreased expression
pattern across all samples. All data for copy number status for each
sample are available as Supplemental ﬁle 3.
3.3. LOH, copy number analysis
Alleles were called using the BRLMM algorithm in Affymetrix
Genotyping Console. The allelic ratio plots of the SNPs at each reported
LOH events were visually examined and any that were found in regions
of poor probe density or close to centromeres were excluded. For exam-
ple, regions on 16p11.2 and 16q11.2 (chr16: 31,325,558–47,050,362)
bordered the centromere and were categorized as copy neutral LOH
events in 9/12 tumors, however visual inspection suggested that these
were SNP-poor regions as shown in Fig. 6 and these were excluded
from further analysis. These were also the most frequent events
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and 10 cm (7–10/12).
As with copy numbers, the LOH regions are also reported in the
number of samples as a range because the HMM algorithm deﬁnes
regions based upon the number of samples with the LOH event.
Fig. 7 shows the composite for each site studied. In order to omit
any regions with poor probe densities (such as that shown in Fig. 6 on
chromosome 16), we divided the number of markers by the length of
the fragment in Kb and omitted any regions with less the 1.016 average
fragments/Kb. Two regions on chromosome 14 were deﬁned as copy
neutral LOH events at 1, 5 and 10 cm from the tumor. The ﬁrst was at
14q23.1 (chr14: 59,890,224–61,197,016), a 1.0 MBP region with 16
genes/ESTs mapping to it. This region was detected in the largest num-
bers of all samples including 6–9/12 samples at 1 cm, 5–9/12 samples at
5 cmand 5–8/12 at 10 cm from the tumor. Interestingly, this LOH event
was only detected in 2–5 of the tumor samples and in some samples it
was a copy neutral event whereas in others it was classiﬁed as a LOH
with accompanying copy number loss and LOH with an accompanying
copy number gain. Of the genes mapping to this region, GPR135,
L3HYPDH, SIX6, SIX1 and 3 ESTs (AL833129, AW627948, BE467658)
had decreased expression compared to the baseline.
The second region on chromosome 14q23.3 with copy neutral LOH
spanned the 1.1 MBP region (chr14: 65,772,609–66,967,075) was de-
tected in 4–8/12 tumors. In the 1 cm samples, the start of this region
shows 4 samples with a deletion accompanying the copy number and
further along the same region this became a copy neutral event in 8
samples. The 5 cm samples have this region reported as a copy neutral
event in 5–8/samples and 5 of the 10 cm samples have this as a copy
neutral event. None of the genes mapping to the region however,
were included in our deﬁnition of not signiﬁcantly changed across all
samples.
A region on chromosome 2 was detected as a copy neutral event in
6–7/12 tumors, 5–6/12 of the 1 cm samples and 6–7/12 samples at
both 5 cm and 10 cm samples. This copy neutral event is a .5 MBP
gene-rich region at 2p13.1 (chr2: 74,330,569–74,847,925) containing
91 genes and ESTs. Of these, EGR4, FBXO41, ACTG2, SLC4A5, RTKN,
LOXL3, SEMA4F, TACR1 and FAM176A have decreased levels of expres-
sion compared to the mean baselines for these genes.Fig. 6. Allelic Ratio Plot of Chromosome 16. Each dot on the plot represents a speciﬁc SNP.
The dots at the zero line are AA calls, at the line labeled 0.50 are AB calls and at the 1.00 line
are BB calls. This chromosome has no LOH, however, because there is a paucity of SNPs
mapping to the region surrounding the centromere, this is called an LOH event while it
is really an artifact of this array.A similar situation was found on chromosome 4p15.1 (chr4:
33,074,782–34,203,253) whereby a copy neutral LOH event was de-
tected in this 1.1 MBP region in 7/12 1 cm, 5 cm and 10 cm samples
but only in 5 of the tumor samples. Two ESTs were mapped to this
region but neither met the criteria for inclusion in our analysis.
On chromosome 12q24.21 (chr12: 110,277,422–111,372,324) a
copy neutral LOH event was detected in 8 tumors 7 samples from
1 cm, 5 cm and 10 cm distal to the tumor. At this locus, patient P has
this LOH event exclusively in the tumor but not in the other samples
while the event was detected in all the same patients in the sites distal
to the tumor. Of the 91 genes/ESTs mapping to the region, TCTN1,
HVCN1, CCDC63, MYL2, BF672169 and BF445961 displayed decreased
expression levels. All LOH data for each sample are available in Supple-
mental File 4.
4. Discussion
The gene showing the highest expression level increase between the
tumor cells and adjacent epithelial cells was TGFB1. Recent studies re-
ported that many tumors, including colon cancer cells, can secrete
TGFB1. It is known that TGFB1 serves as a tumor suppressor in the nor-
mal intestinal epithelium by inhibiting cell proliferation and inducing
apoptosis. Many colorectal cancers escape the tumor-suppressor effects
of TGFB1 and the TGFB1-induced growth inhibition is abolished in colo-
rectal cancer cells as a consequence ofmutations of various downstream
signaling agents, such as p53, which fail to respond to TGFB1 stimula-
tion [16]. Polymorphisms in the C allele of TGFB1−509 CNT and the A
allele of−800 GNA have been associatedwith an increased risk of colo-
rectal cancer [17]. TGFB1 over expression has also been associated with
epithelial-mesenchymal transition (EMT) in colorectal cancer [18].
Our analysis also identiﬁed FOXQ1 as 170-fold up-regulated in the
tumor samples compared to the adjacent epithelial samples. FOXQ1
has been previously reported to be overexpressed in colorectal cancer
and enhances tumorigenicity and tumor growth presumably through
its angiogenic and antiapoptotic effects [19]. Others have reported that
FOXQ1 also mediates EMT in cancer cell lines through transcriptional
inactivation of CDH1 [20]. In our analysis CDH1 was marginally down-
regulated (1.6-fold) in the tumor cells.
FN1 overexpression has also been reported to be involved in EMT
[21]. Other up-regulated genes identiﬁed by the comparison of tumor
and isolated adjacent epithelial cells have also been previously reported
by others including IGFBP7 [22], TIMP1 [23], PHLDA [24] and NME [25].
In a recent study we found that COL6A1, FN1 and CALD1 were all alter-
natively spliced in colorectal cancer [11]. Most of the genes with the
maximum decreased expression levels have also been previously re-
ported AQP8, GUCA2A, GUCA2B, CLCA4, CA4, ZG16 [11], CD177[26],
MS4A12 [27], TRPM6 [28], ABCG2 [29] and OSTBeta [30].
Colorectal cancers arise sporadically due to multiple somatic muta-
tions and genetic instability. Genetic instability includes microsatellite
instability (MSI), chromosomal instability (CIN) or the concordant
methylation of the C–G di-nucleotides in the promoter region of multi-
ple genes is called CpG Island Methylator Phenotype [31]. The delinea-
tions of these pathways have not been completely elucidated and they
are not mutually exclusive so that a single tumor may show features
of multiple pathways. The pathway with the highest enrichment score
identiﬁed by the transcript expression comparison of tumor cells com-
pared to adjacent epithelial cells was the Mismatch Repair pathway
(MMR). Approximately 15% of sporadic colorectal cancers demonstrate
increased levels of microsatellite instability and in themajority of these
cases this is attributable to the transcriptional silencing of the MLH1
gene through promotor methylation [32]. In the pathway shown in
Fig. 3, it was noted that all pathway elements show increased expres-
sion in the tumor cells, except for PMS2 and MSH3 which do not have
any difference in gene expression between the tumor and normal
cells. Based on the incidence of sporadic tumors showing microsatellite
instability and the up-regulation of most of the genes in this pathway,
Fig. 7. LOH of A. tumor cells, B. cells isolated 1 cm from the tumor, C. cells isolated 5 cm from the tumor and D. cells isolated 10 cm from the tumor. The samples are in alphabetical order
starting with Patient A, closest to the chromosome on the left, and ending with Patient P The p-arm of chromosome 1 shows consistent LOH. Chromosomes 2p, 4p and 12q, as well as 2
adjacent regions on chromosome 14 all show consistent LOH across all samples.
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either by mutations or epigenetic silencing of the MMR pathway.
CIN is the most common type of genomic instability observed in co-
lorectal cancer and occurs in 80–85% of sporadic cases. As discussed
above, the p53 pathway also was identiﬁed by our analyses as was the
colorectal cancer pathway and there is considerable overlap between
the two pathways. We noted that the TP53 was up-regulated while
the cell cycle arrest target genes CDKN1A (p21), YWHAQ and GADD45
are down-regulated, however the down-stream targets of these
genes CCND1/CDK4/6, CCNE1/CDK2, CCNB1/CDK1 are all up-regulated
suggesting that cell cycle arrest is not activated in these tumor
cells. However, many oncogenic signals are capable of inducing the
CCND1/CDK4/6 heterodimer expression and do so through distinct
DNA sequences in the cyclin D1 promoter including KRAS, SRC, ERBB2
CTNNB1 and STAT1.Our transcript expression analysis of tumor compared to “normal”
epithelial cells represents one of the ﬁrst using isolated cells from
these regions. Interestingly the ﬁndings are very similar to other studies
which have used whole tissue isolation methods.
Our copy number analyses conﬁrm that the tumor samples had
many copy number alterations frequently associated with colorectal
cancer including gains on chromosome 7, 8q, 13q and 20q and losses
on 4, 8p, 17p and 18. For example, 13q34 ampliﬁcation was detected
in 11/12 tumors. The RAB20 gene maps to this region. Recently
Habermann et al. [32] found that RAB20was ampliﬁed in 34% of tumors.
They suggested that this RAS-GTPase family member is expressed on
the apical surface of the epithelial cells and is involved in endocytosis
and recycling. The high expression level of this gene could account for
increased recycling of growth factor receptors required for tumor prolif-
eration. LAMP1 alsomaps to this region andwas over-expressed in all of
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lumenal carbohydrate side chains form a coat on the inner surface of the
membrane. It has been suggested that these glycoproteins serve as a
barrier against the hydrolytic activity of the lysosomal enzymes and
thereby prevent accidental release of lysosomal constituents into the
cytosol. LAMP1 and LAMP2 have been reported to be overexpressed in
several different malignancies and the increased expression is thought
to be the direct result of the neoplastic cells up-regulating the expres-
sion of the lysosomal cysteine cathepsins [33].
The next most commonly detected gain was on chromosome 8q.
BOP1 maps to this region, is involved in ribosome biogenesis and has
been reported to be increased in colorectal cancer and is associated
with multipolar spindle formation [34]. Increased HSF1 expression has
also previously been reported. HSF1 induces the heat shock signaling
pathway which is critical in carcinogenesis since the proteins in the
pathway impact downstream proteins involved in signal transduction,
cell cycle progression and apoptosis [35]. Ampliﬁcations of MYC are
commonly associated with colorectal cancer and the ampliﬁcation
on 8q23–24 is often considered the driving force behind this, not-
withstanding, MYC mapped outside of the region of minimal overlap
on 8q23–q24 in our studies. MYC had higher expression levels in the
tumors compared to the surrounding regions in all patient samples
(average of 47 fold increase) which suggest that MYC is expressed
later in tumorigenesis. This ﬁnding is supported by Habermann et al.
[32] where expression levels of MYC were found to increase from
adenoma to carcinoma progression in the same patients.
Loss of chromosome 8p21–p22 has been reported as a frequent
event in CIN colorectal cancer and has been associated with in-
creased metastases and progression. Our studies suggest that this is
an early event as it is detectable 10 cm away from the tumors. Inter-
estingly, this loss has also been detected in malignant colorectal
polyps [36]. STC1 maps within this region and previous studies
have shown that, STC1 is a HIF1 target gene and was epigenetically
regulated by histone deacetylation [37] and more recently, Sp-1
[38]. STC1 overexpression results in apoptosis of colorectal cancer
cells in culture and under-expression is associated with increased
cellular proliferation.
LOH events were found to show more consistent relationship
between the tumor and adjacent tissue. Despite this fact, few of the
genes mapping to these regions showed loss of expression when we
compared the expression across all samples to a normalized baseline
and one of the genes had been reported in colon cancer previously
and did not present as likely tumor suppressor genes capable of driving
tumorigenesis. A more extensive analysis of mutations in CRC mapping
to these regions of LOH may shed light on their role.
We have performed array analysis of copy number LOH and tran-
script expression to determine if the concept ofﬁeld effect cancerization
is discernible at the molecular level. Copy number events strongly
reﬂected widespread genomic instability and are not consistent across
all samples. The data strongly suggests that the regions surrounding
the tumor, as far distal as 10 cm, have levels of chromosomal instability.
The fact that some regions are detected in the tumor and 10 cm distal
but not at 1 or 5 cm strongly suggests that this instability is not consis-
tent from cell to cell. The data tend to support the Mutator Phenotype
theory of Loeb et al. [10], which states that the genotypes of most cells
within a tumor would not be identical, but would share at least a single
mutation in any number of genes, or a selection of genes affecting a
speciﬁc pathway which proffer a proliferative advantage. The tumor it-
self would develop as a heterogeneous collection of cells all sharing a
common feature of chromosomal instability. Although limited to 12 pa-
tients, our results suggest that the tumor progression model put for-
ward by Fearon and Vogelstein [7] is less likely than widespread
chromosomal instability at the cellular level. We cannot rule out the
clonal expansion theory proposed by Nowell [9] because the detection
of changes using the SNP arrays requires that at least 15–20% of the
cells in the sample must carry the alteration detected by the arrays.Our studies found multiple smaller copy number alterations in the
areas surrounding the tumor which were not always consistent across
the ﬁeld. These alterations become larger and more frequent in the ac-
tual tumor and this progression of chromosomal instability is unques-
tionably supported by other events associated with tumor progression
such as, aneuploidy, impairment of DNA repair mechanisms and chro-
mosomal breakage. The concept that at least one or more mutated
genes which common pathways are involved in ﬁeld effect and tumor-
igenesis suggests that next generation sequencingmight bemore effec-
tive in producing candidate genes for screening surrounding tissues for
possible tumor recurrence.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygeno.2013.11.003.References
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